Informations générales (source: ClinicalTrials.gov)
Description of Lung Transplant Patients With Microbiologically Documented Stenotrophomonas Maltophilia Pneumonia and Impact of Treatment on Outcome (STENO_SOT)
Observational
Fondation Hôpital Saint-Joseph (Voir sur ClinicalTrials)
novembre 2021
décembre 2023
29 juin 2024
Stenotrophomonas maltophilia is a multi-resistant Gram-negative bacillus and is an
opportunistic pathogen. Stenotrophomonas maltophilia infections are associated with a
significant morbidity and mortality, particularly in immunocompromised patients. The
mortality of infections (bacteremia, pneumonia) related to Stenotrophomonas maltophilia
is variable and is estimated between 21 and 69%. Stenotrophomonas maltophilia
pneumopathies have been mainly described in patients hospitalized in intensive care and
benefiting from mechanical ventilation. The existence of immunosuppression seems to be a
risk factor for the transition from Stenotrophomonas maltophilia pulmonary colonization
to Stenotrophomonas maltophilia pulmonary infection. The reference treatment for
Stenotrophomonas maltophilia-associated pneumonia is the combination of trimethoprim and
sulfamthoxazole, a molecule that lung transplant patients routinely receive as a
preventive treatment for Pneumocysitis jirovecii infection. There is no consensus on the
value of routine dual-antibiotic therapy, and it varies from one center to another and
from one country to another.
The main objective is to compare the clinical-microbiological evolution of lung
transplant patients treated for Stenotrophomonas maltophilia pneumopathy according to the
prescription of a mono- or bi-antibiotherapy.
The secondary objective is to evaluate the resistance rate of Stenotrophomonas
maltophilia strains isolated from respiratory samples according to the anti-pneumocystis
prophylactic molecule received by the patient.
Etablissements
| Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| GH PARIS SITE SAINT JOSEPH | Benoit PILMIS, MD | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- Patient whose age ≥ 18 years
- Patient who has received a lung (mono or bi-pulmonary) or heart-lung transplant
- Patient with documented pneumopathy (clinico-radiological definition) (positive
respiratory specimen for Stenotrophomonas maltophilia)
- French speaking patient
- Patient whose age ≥ 18 years
- Patient who has received a lung (mono or bi-pulmonary) or heart-lung transplant
- Patient with documented pneumopathy (clinico-radiological definition) (positive
respiratory specimen for Stenotrophomonas maltophilia)
- French speaking patient
- Patient under guardianship or curatorship
- Patient deprived of liberty
- Patient under court protection
- Patient objecting to the use of his data for this research